The one-drug regimen is widely viewed as a backup plan if higher courts uphold Judge Kacsmaryk’s ruling blocking approval for mifepristone.
The one-drug regimen is widely viewed as a backup plan if higher courts uphold Judge Kacsmaryk’s ruling blocking approval for mifepristone.